Janssen’s Stelara gets FDA nod for adolescent indication

SILVER SPRING, Md. — Janssen Biotech’s Stelara (ustekinumab) has a new indication. The Food and Drug Administration on Monday approved the drug to treat adolescents ages 12 years and older with moderate-to-severe plaque psoriasis.

According to the World Health Organization, roughly one-third of patients diagnosed with plaque psoriasis is younger than 20 years of age, and adolescents in particular have limited treatment options.

“Psoriasis can affect many aspects of everyday life and the visible plaques, itching and discomfort can take a particular toll on adolescents,” Janssen VP medical affairs Dr. Andrew Greenspan said. "With today's approval, Stelara has the potential to make a meaningful difference in the lives of these young adults."